Skip to main content
. 2021 Feb 3;26(4):778. doi: 10.3390/molecules26040778

Figure 2.

Figure 2

(Reprinted with permission from [39]) Plot of the change from baseline in average weekly WOMAC pain with walking scores through week 24 in patients treated with intra-articular capsaicin (CNTX-4975, specifically) versus placebo is shown. A mixed model for repeated measures was used in the modified intent-to-treat population. Week 12 was the prespecified landmark endpoint. Baseline scores (range 0–10): placebo 7.4, CNTX-4975 0.5 mg 7.2, CNTX-4975 1.0 mg 7.2. * = P < 0.1; † = P < 0.05; ‡ = P < 0.001 versus placebo.